BBI 2000

Drug Profile

BBI 2000

Alternative Names: BBI-2000; BBI-2111

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Syngenta
  • Developer Brickell Biotech
  • Class Anti-inflammatories; Antiallergics; Peptides; Thioredoxins
  • Mechanism of Action Cell movement inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic contact dermatitis

Most Recent Events

  • 24 May 2017 Brickell Biotech completes a phase I trial in Allergic contact dermatitis (In volunteers) in Canada (NCT03089775)
  • 14 Mar 2017 Phase-I clinical trials in Allergic contact dermatitis (In volunteers) in Canada (Topical) (NCT03089775)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top